Skip to main content

Advertisement

SpringerLink
Log in

Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility in Japanese rheumatoid arthritis patients

  • Letter
  • Published:
Modern Rheumatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Criswell LA, Pfeiffer KA, Lum RF, et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet. 2005;76:561–71.

    Article  PubMed  CAS  Google Scholar 

  2. Kobayashi S, Ikari K, Kaneko H, et al. Association of STAT4 with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Japanese population. Arthritis Rheum. 2008;58:1940–6.

    Article  PubMed  Google Scholar 

  3. Tsuchiya N, Kawasaki A, Hasegawa M, et al. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. Ann Rheum Dis. 2009;68:1375–6.

    Article  PubMed  CAS  Google Scholar 

  4. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007;39:857–64.

    Article  PubMed  CAS  Google Scholar 

  5. Shibuya A, Campbell D, Hannum C, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4:573–81.

    Article  PubMed  CAS  Google Scholar 

  6. Hafler JP, Maier LM, Cooper JD, et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun. 2009;10:5–10.

    Article  PubMed  CAS  Google Scholar 

  7. Maiti AK, Kim-Howard X, Viswanathan P, et al. Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility to multiple autoimmune diseases. Rheumatology (Oxf). 2010;49:1239–44.

    Article  CAS  Google Scholar 

  8. Du Y, Shen LX, Yu LK, et al. The CD226 gene in susceptibility of rheumatoid arthritis in the Chinese Han population. Rheumatol Int. 2011 [Epub ahead of print]

  9. Chen R, Wei Y, Cai Q, et al. The PADI4 gene does not contribute to genetic susceptibility to rheumatoid arthritis in Chinese Han population. Rheumatol Int. 2011;31:1631–4.

    Article  PubMed  CAS  Google Scholar 

  10. Ikari K, Kuwahara M, Nakamura T, et al. Association between PADI4 and rheumatoid arthritis: a replication study. Arthritis Rheum. 2005;52:3054–7.

    Article  PubMed  CAS  Google Scholar 

  11. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.

    Article  PubMed  CAS  Google Scholar 

  12. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.

    Article  PubMed  CAS  Google Scholar 

  13. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–90.

    Google Scholar 

  14. Ikari K, Momohara S, Inoue E, et al. Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population. Rheumatology (Oxf). 2006;45:1345–8.

    Article  CAS  Google Scholar 

  15. Iwamoto T, Ikari K, Nakamura T, et al. Association between PADI4 and rheumatoid arthritis: a meta-analysis. Rheumatology (Oxf). 2006;45:804–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank all of the DNA donors for making this study possible. We are grateful to Ms. Yukiko Kenyoshi for her technical efforts. We also appreciate Mr. Eisuke Inoue and other members of the Institute of Rheumatology, Tokyo Women’s Medical University for their efforts with the IORRA cohort. This work was supported by a Grant-in-Aid for Young Scientists (A) from the Japan Society for the Promotion of Science (20689029 to K.I.). The IORRA cohort was supported by unrestricted research grants from 40 pharmaceutical companies: Abbott Japan Co., Ltd., Asahikasei Kuraray Medical Co., Ltd., Asahikasei Pharma Corporation, Astellas Pharma Inc., AstraZeneca K.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi Fine Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Dentsu, Sudler & Hennessey Inc., Eisai Co., Ltd., GlaxoSmithKline K.K., Hisamitsu Pharmaceutical Co., Inc., Janssen Pharmaceutical K.K. Japan Tobacco Inc., Kaken Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Maruho Co., Ltd., Mitsubishi Chemical Medience Corporation, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Mundiphama K.K., Nippon Chemiphar Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi-Aventis K.K, Santen Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sekisui Medical Co., Ltd., Shionogi Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd., Teijin Pharma Ltd., Torii Pharmaceutical Co., Ltd., UCB Japan Co., Ltd., and Zeria Pharmaceutical Co., Ltd. S.M. has received lecture fees and/or honoraria from Abbott Japan, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Santen Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Company Ltd. H.Y. has received lecture/consulting fees from Abbott Japan, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Hoffmann-La Roche, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., and Takeda Pharmaceutical Company Ltd.

Conflict of interest

The authors declare that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada, Shinjuku, Tokyo, 162-0054, Japan

    Taku Suzuki, Katsunori Ikari, Yasushi Kawaguchi, Koichiro Yano, Takuji Iwamoto, Manabu Kawamoto, Atsuo Taniguchi, Hisashi Yamanaka & Shigeki Momohara

  2. Department of Orthopaedic Surgery, Keio University, Tokyo, Japan

    Taku Suzuki, Takuji Iwamoto & Yoshiaki Toyama

Authors
  1. Taku Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katsunori Ikari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasushi Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koichiro Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuji Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manabu Kawamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshiaki Toyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Atsuo Taniguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hisashi Yamanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shigeki Momohara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katsunori Ikari.

About this article

Cite this article

Suzuki, T., Ikari, K., Kawaguchi, Y. et al. Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility in Japanese rheumatoid arthritis patients. Mod Rheumatol 23, 200–202 (2013). https://doi.org/10.1007/s10165-012-0609-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-012-0609-x

Keywords

Search

Navigation